Healthcare lacks scalable disease intelligence tools
Brain health is our first application
-
Early detection and patient stratification are critical to therapy success and clinical trials.
-
Clinicians, healthcare systems and pharmaceutical companies lack scalable disease-intelligence tools.
-
Existing approaches are expensive, specialist-dependent and capture only a fraction of the available biological information.
-
Disease intelligence is increasingly required for personalized medicine, monitoring and therapeutic development.
Current pathways often rely on a combination of cognitive assessments, specialist evaluation, imaging and biomarker testing. These approaches can be expensive, capacity constrained and poorly suited to large-scale deployment, monitoring and personalized intervention.
The challenge is not simply diagnosing disease earlier, but generating the disease intelligence needed to guide interventions, monitor progression and accelerate therapeutic development.